Iurii Rudyk

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4006367/publications.pdf Version: 2024-02-01

		840119	1125271
21	12,064	11	13
papers	citations	h-index	g-index
21	21	21	13844
all docs	docs citations	times ranked	citing authors

אירוו דישוו

#	Article	IF	CITATIONS
1	Edoxaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2013, 369, 2093-2104.	13.9	4,215
2	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine, 2017, 376, 1713-1722.	13.9	4,179
3	Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. New England Journal of Medicine, 2013, 369, 1327-1335.	13.9	2,261
4	Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk. JAMA - Journal of the American Medical Association, 2019, 321, 69.	3.8	830
5	Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity and Metabolism, 2009, 11, 611-622.	2.2	272
6	Cause of Death and Predictors of All ause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. Journal of the American Heart Association, 2016, 5, e002197.	1.6	127
7	Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation. Circulation, 2019, 139, 787-798.	1.6	60
8	Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. American Heart Journal, 2019, 213, 35-46.	1.2	45
9	Management and 1‥ear Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELDâ€AF Registry. Journal of the American Heart Association, 2019, 8, e010510.	1.6	44
10	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. Indian Heart Journal, 2018, 70, 828-835.	0.2	16
11	Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELDâ€AF and treated with vitamin K antagonists. British Journal of Haematology, 2016, 174, 610-623.	1.2	13
12	TNFa and Serum Galectin-3 in Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction, Insulin Resistance and Type 2 Diabetes Mellitus. Journal of Cardiac Failure, 2014, 20, S24.	0.7	1
13	Association of M235T polymorphism of angiotensinogen gene, ST2 level and lipid parameters in heart failure patients with type 2 diabetes mellitus. Atherosclerosis, 2018, 275, e249.	0.4	1
14	The influence of bisoprolol on lipids metabolism in patients with heart failure and systolic dysfunction depending on beta1-adrenergic receptor gene polymorphism. Atherosclerosis, 2015, 241, e141.	0.4	0
15	PREDICTION MODEL FOR CARDIOVASCULAR EVENTS IN HYPERTENSIVE PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION AND TYPE 2 DIABETES MELLITUS. Journal of Hypertension, 2019, 37, e142.	0.3	0
16	Influence of Diabetes and M235Tangiotensinogen Gene Polymorphism on Lipid Metabolism in Patients with Heart Failure. Metabolism: Clinical and Experimental, 2021, 116, 154682.	1.5	0
17	MANAGEMENT OF PATIENTS WITH HEART FAILURE AND COVID-19. Journal of the National Academy of Medical Sciences of Ukraine, 2021, , 38-48.	0.1	0
18	Forecasting the course of a heart failure in patients with a non-toxic goiter, accounting function of the thyroid gland. ScienceRise: Medical Science, 2020, .	0.0	0

Iurii Rudyk

#	Article	IF	CITATIONS
19	Overview of the impact β1-adrenergic receptor gene polymorphisms have on the progression of heart failure. Journal of the National Academy of Medical Sciences of Ukraine, 2019, , 296-305.	0.1	ο
20	Association of tumor necrosis factor-alpha and lipid parameters in patients with coronary heart disease and heart failure. Atherosclerosis, 2020, 315, e226.	0.4	0
21	Association between ultrasonographic parameters, clinical and biochemical indicators and results of surveys in patients with heart failure with moderately reduced left ventricle fraction. ScienceRise: Medical Science, 2022, , 9-14.	0.0	Ο